ImPact Biotech
Manufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
16 Einstein St, Ness Ziona, Central Dist...Phone Number
+972 747115351Website
www.impactbiotech.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About ImPact Biotech
ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination for selective ablation of unresectable solid tumors. The novel VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment. Padeliporfin VTP is currently being evaluated in a pivotal Phase 3 study in low-grade upper tract urothelial carcinoma (UTUC) with earlier stage studies ongoing or planned in high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The Company has longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operations in the EU, Israel and the US.Explore more
ImPact Biotech Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ImPact Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once ImPact Biotech has new funding data
Check if ImPact Biotech has recently received funding, and reach out quickly before it becomes old news!
Click to see if ImPact Biotech had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at ImPact Biotech
Check out if ImPact Biotech is spiking on competitors!
ImPact Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on ImPact Biotech recently announced quarterly report
Product Launch: Get notified when ImPact Biotech launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
ImPact Biotech is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ImPact Biotech is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ImPact Biotech.
ImPact Biotech Tech Stack
A closer look at the technologies used by ImPact Biotech
See more technologies
ImPact Biotech News & Media
ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026
– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed Primary Response Evaluation (PRE) –ImPact Biotech Announces Upcoming Data Presentations for Padeliporfin VTP at AUA and ASCO 2026
– Company to present updated data from the Phase 3 ENLIGHTED trial of Padeliporfin VTP in LG UTUC with topline data expected in 2026 –ImPact Biotech Presents Preliminary Data from Phase 1 Study of Padeliporfin VTP in LA-PDAC at SIR 2026 and Provides Strategic Business Update
– Initial data from first cohort in LA-PDAC show 66% (2/3) patients resected following VTP at lowest light dose with a consistent and well-tolerated safety profile – – LA-PDAC program represents large market opportunity in highest unmet need patients, with potential for accelerated registrational pathway; additional results from Phase 1 trial expected in 2026 –ImPact Biotech Presents Updated Preliminary Data from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at SUO 2025
– Complete response (CR) observed in 70% (35/50) of patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP)
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ImPact Biotech
Sign Up For FreeTo access detailed company insights
ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination for selective ablation of unresectable solid tumors. The novel VTP platform delivers non-thermal laser light via optical fibers to l... Read More
